Semax Amidate · Research brief

What Is Semax? (Peptide Structure, Formats, Handling)

Real Peptides Research TeamEditorial

Updated September 30, 202610 min read

60 WORDS

Short answer

Most search results file semax under the label 'nootropic', and that is exactly where the confusion starts. It is not a stimulant. It is not a hormone. It is not an approved medicine in the United States. Semax is a synthetic heptapeptide, seven amino acids in the sequence Met-Glu-His-Phe-Pro-Gly-Pro, built from a fragment of adrenocorticotropic hormone with the hormone-triggering portion…

Key takeaways

Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro, derived from the ACTH(4-10) fragment of adrenocorticotropic hormone and carrying no corticotropic activity.
The Pro-Gly-Pro extension is what makes semax experimentally usable, because the parent ACTH(4-10) fragment is degraded by peptidases within minutes.
Intranasal solution formats dominate the published literature because oral delivery destroys the peptide and systemic delivery crosses the blood-brain barrier poorly.
Semax is registered as a medicine in Russia but is not FDA-approved, and in the United States it is supplied for laboratory research only.
Lyophilised peptide stores at minus 20 degrees Celsius; once reconstituted, solution belongs at 2 to 8 degrees Celsius and degrades with every freeze-thaw cycle.
A certificate of analysis should report both HPLC purity and net peptide content, because those two numbers answer completely different questions.

We supply research-grade peptides to laboratories, and semax generates more questions per order than almost anything else we ship. Our team hears the same three every week: what the molecule actually is, why nearly every published protocol uses a nasal solution format, and how to keep reconstituted material from degrading before the work is finished.

What is semax?

Semax is a synthetic seven-amino-acid peptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from the ACTH(4-10) fragment of adrenocorticotropic hormone, with a Pro-Gly-Pro tail attached to resist enzymatic breakdown. It carries no corticotropic activity, meaning it does not trigger cortisol release. Registered as a medicine in Russia, semax is not FDA-approved and is supplied in the United States strictly for laboratory research.

The oversimplification worth correcting: calling semax a nootropic describes a marketing category, not a mechanism. The peer-reviewed work sits mostly in neuroprotection, neurotrophic signalling and cerebral ischaemia models rather than healthy-brain enhancement, and a large share of it was published in Russian-language journals that Western reviewers rarely cite. What follows covers the molecule's structure and origin, why intranasal solution formats dominate the literature, what the studies and tolerability reports actually describe, and how research-grade material should be stored, verified and documented.

The molecule: a stress-hormone fragment with the hormone part removed

Semax is a synthetic analog of ACTH(4-10), the short stretch of adrenocorticotropic hormone that carries behavioural and memory-related activity in animal models without driving the endocrine response. ACTH itself is the pituitary hormone that signals the adrenal cortex to produce cortisol. The 4-10 fragment keeps the neuroactive behaviour and drops the hormonal one, which is the entire point of the design.

That fragment had a practical flaw severe enough to make controlled work almost impossible. Plasma and tissue peptidases degrade it within minutes. Researchers associated with the Institute of Molecular Genetics of the Russian Academy of Sciences addressed it by attaching Pro-Gly-Pro to the C-terminus, a protease-resistant motif that gives the molecule far greater stability than the parent fragment while leaving the active N-terminal region intact.

What the literature reports about mechanism is genuinely interesting and genuinely incomplete. Published animal work describes increased expression of BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor) in hippocampal tissue following semax exposure, alongside modulation of dopaminergic, serotonergic and cholinergic signalling and interaction with enkephalin-degrading enzymes in the endogenous opioid system. Research suggests these effects converge on neuroprotection rather than acting through one clean target. No high-affinity receptor specific to this peptide has been characterised, which is a large part of why the pharmacology remains contested.

In our experience this is the detail researchers most often get wrong on first contact. Semax does not behave like a receptor agonist with a tidy dose-response curve. It behaves like a regulatory peptide with diffuse downstream effects.

Why nasal solution formats dominate the published research

Nearly every published semax protocol uses an intranasal solution because the peptide is destroyed by gastric and intestinal proteases when given orally and penetrates the blood-brain barrier poorly from systemic circulation. Intranasal delivery exploits the olfactory and trigeminal nerve pathways in the upper nasal cavity, which offer a partial direct route from mucosa to brain tissue and bypass first-pass hepatic metabolism entirely. That is why searches for semax spray and nasal solution formats outnumber searches for the powder: the solution is the format the research was built around.

Here is the part most overview pages miss. The Pro-Gly-Pro tail is usually described as inert armour, a protective cap that slows degradation and does nothing else. That framing is probably wrong. When peptidases eventually clip the molecule, PGP is released as a free tripeptide, and PGP belongs to the glyproline family, which carries its own documented biological activity in the literature. The degradation product of semax may not be pharmacologically silent. Any study design that assumes clean inactivation on breakdown is making an assumption the chemistry does not support.

So what do the studies actually report? Published work spans cerebral ischaemia and stroke models, attention and memory tasks, optic nerve injury and anxiety-related behaviour, with most reports describing the compound as well tolerated and mild local nasal irritation as the complaint that recurs most often in solution-format work. The samples are small. Independent Western replication is thin.

Our team reads new semax papers as they index, and the pattern has not shifted in years: interesting mechanism, modest evidence.

Storing and verifying research-grade semax

The compound ships in two practical formats: lyophilised powder in a sealed vial, and pre-mixed liquid solution supplied with a spray or dropper fitting. A third variant, N-acetyl semax amidate, modifies both ends of the molecule by acetylating the N-terminus and amidating the C-terminus, a change the literature associates with greater resistance to enzymatic cleavage than the unmodified sequence.

Storage is where most material is quietly lost. Lyophilised peptide holds up well for extended periods at minus 20 degrees Celsius, kept dry and dark. Once reconstituted, solution belongs at 2 to 8 degrees Celsius with a much shorter usable window, and repeated freeze-thaw cycling drives aggregation and loss of net peptide content that no visual inspection will reveal. At low concentrations, peptide also adsorbs onto glass and plastic, pulling real concentration below the calculated figure.

Read the certificate of analysis for two numbers, not one. HPLC purity states what proportion of the peptide present is the correct sequence. Net peptide content states how much of the vial's gross weight is peptide rather than counterions, residual trifluoroacetic acid and bound water. A vial can be 99 percent pure by HPLC and still hold meaningfully less peptide than the label weight implies.

One boundary stated plainly: the question 'how to use semax nasal spray' has no consumer answer here. In a laboratory, use means documented handling under institutional oversight, with labelled storage, a temperature log and a written protocol. Semax is not a veterinary product either, and any question about an animal's health belongs with a licensed veterinarian. This information is educational, describing research literature and laboratory practice rather than human or animal use.

Comparing Semax research formats side by side

The formats a laboratory encounters differ less in the active sequence than in stability, handling burden and documentation. This table sets out what each one actually demands before an experiment begins.

Format	What it is	Stability profile	Handling burden	Professional assessment
Lyophilised semax powder	Freeze-dried peptide sealed in a vial under vacuum or inert gas	Longest shelf stability when held at minus 20C, dry and protected from light	Requires reconstitution, accurate solvent measurement and a dated concentration label	The right call when concentration control and long storage matter more than convenience
Semax liquid spray solution	Pre-reconstituted solution supplied in a metered spray or dropper fitting	Shortest usable window; refrigeration at 2 to 8C and light protection are non-negotiable	Lowest preparation burden, but no control over the concentration as supplied	Suits short, tightly scoped studies where the supplied concentration matches the protocol exactly
N-acetyl semax amidate	Terminally modified analog, acetylated at the N-terminus and amidated at the C-terminus	Literature reports greater resistance to enzymatic cleavage than the unmodified sequence	Same as lyophilised powder, plus separate documentation as a chemically distinct compound	Use when the research question concerns the modified analog itself, never as a drop-in substitute
ACTH(4-10) parent fragment	The unmodified precursor sequence the heptapeptide was derived from	Degraded by peptidases within minutes in biological matrices	Impractical for most in vivo designs without stabilisation	A reference compound for comparison work, rarely the experimental subject

What If: Laboratory Handling Scenarios

What if the vial arrives warm?

Quarantine it, log the temperature excursion, and contact the supplier before reconstituting anything. Lyophilised semax tolerates short ambient excursions considerably better than solution does, because water is the medium in which hydrolysis and aggregation happen. Pre-mixed spray formats are the vulnerable case. There is no bench test short of HPLC that will tell you whether a warm shipment lost potency, and appearance proves nothing either way.

What if the vial looks empty?

Do not assume the peptide is missing. A few milligrams of lyophilised semax often forms a translucent film on the vial wall or a puck so thin it reads as empty under fluorescent light. Check the stated net peptide content on the certificate of analysis, tilt the vial against a dark background, and reconstitute normally. Vacuum-sealed vials can also draw solvent in faster than expected during reconstitution.

What if the reconstituted solution turns cloudy or shows particles?

Stop using it and document the batch and storage history. Cloudiness, visible particulates or stringing in a previously clear peptide solution generally indicates aggregation, which changes the effective concentration of monomeric peptide in an unpredictable way. Common triggers are freeze-thaw cycling, agitation during mixing and pH shifts from the chosen diluent. Aggregated material cannot be rescued by filtration without invalidating concentration assumptions.

What if a supplier cannot produce a certificate of analysis?

Treat the material as chemically unidentified, regardless of what the label says. A usable certificate names the batch, reports HPLC purity, confirms identity by mass spectrometry and states net peptide content. Unverified semax material introduces an uncontrolled variable into every downstream result, and sequence errors or truncated synthesis products are not visible in a white lyophilised powder.

The unglamorous truth about the evidence base

Here is the honest answer: the semax evidence base is thinner than the internet implies. A large share of the published work is small-sample, Russian-language, and has never been independently replicated in a Western laboratory, and no large randomised controlled trial has been accepted by a regulator outside Russia. That does not make semax uninteresting. The neurotrophic and neuroprotective signals reported in animal models are real published findings. But 'promising in rodent ischaemia models' and 'established cognitive enhancer' are separated by roughly two decades of clinical work that simply has not been done.

Researchers comparing formats can review the specifications for Semax Liquid Spray and the terminally modified Semax Amidate Peptide, read the wider research overview page, check batch documentation in our certificates of analysis library, or work through the full peptide catalog.

Semax occupies an unusual position in peptide science: four decades of research history, routine pharmacy status in one country, and near-total regulatory invisibility everywhere else. That gap is not evidence of suppression, and it is not evidence of a miracle being withheld. It is what happens when a compound is developed inside one research system and never carried through the trial machinery another system demands. For a laboratory, that makes it a legitimate object of study and a poor object of certainty. Read the literature as a hypothesis, not a conclusion.

References

Peer-reviewed sources on Semax indexed in PubMed, listed for research context. Real Peptides supplies Semax for laboratory research use only.

The Potential of the Peptide Drug Semax and Its Derivative for Correcting Pathological Impairments in the Animal Model of Alzheimer's Disease. Acta naturae, 2025. PMID 41479572. doi:10.32607/actanaturae.27808
Semax, a Copper Chelator Peptide, Decreases the Cu(II)-Catalyzed ROS Production and Cytotoxicity of aβ by Metal Ion Stripping and Redox Silencing. Bioinorganic chemistry and applications, 2025. PMID 40496623. doi:10.1155/bca/4226220
Functional Connectomic Approach to Studying Selank and Semax Effects. Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections, 2020. PMID 32342318. doi:10.1134/S001249662001007X
Novel Insights into the Protective Properties of ACTH((4-7))PGP (Semax) Peptide at the Transcriptome Level Following Cerebral Ischaemia-Reperfusion in Rats. Genes, 2020. PMID 32580520. doi:10.3390/genes11060681
Influence of ACTG(4-7)-PGP (Semax) on Morphofunctional State of Hepatocytes in Chronic Emotional and Painful Stress. Bulletin of experimental biology and medicine, 2017. PMID 28577097. doi:10.1007/s10517-017-3748-4
Peptides semax and selank affect the behavior of rats with 6-OHDA induced PD-like parkinsonism. Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections, 2017. PMID 28702721. doi:10.1134/S0012496617030048
Semax prevents learning and memory inhibition by heavy metals. Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections, 2016. PMID 27411820. doi:10.1134/S0012496616030066
The effect of Semax and its C-end peptide PGP on the morphology and proliferative activity of rat brain cells during experimental ischemia: a pilot study. Journal of molecular neuroscience : MN, 2011. PMID 20617398. doi:10.1007/s12031-010-9421-2

Questions

Semax is a synthetic heptapeptide with the amino acid sequence Met-Glu-His-Phe-Pro-Gly-Pro, derived from the ACTH(4-10) fragment of adrenocorticotropic hormone and extended with a protease-resistant Pro-Gly-Pro tail. It carries no corticotropic activity, so it does not stimulate cortisol release. It is registered as a medicine in Russia and supplied in the United States for laboratory research only.

Semax spray is the peptide supplied as a pre-mixed liquid solution in a metered spray or dropper fitting rather than as lyophilised powder. Intranasal solution is the format most published research protocols used, because oral delivery destroys the peptide. Spray formats require refrigerated storage at 2 to 8 degrees Celsius and have a shorter usable window than powder.

There is no consumer use instruction, because this compound is a research-use-only material and not an approved medicine. In a laboratory setting, use means documented handling under institutional oversight: verified certificate of analysis, labelled and dated storage at 2 to 8 degrees Celsius, a temperature log, and a written protocol approved before any experiment begins.

Published animal and small clinical studies describe neuroprotective and neurotrophic effects, including increased expression of BDNF and NGF in hippocampal tissue, alongside work in cerebral ischaemia models, attention and memory tasks, optic nerve injury and anxiety-related behaviour. Research suggests a neuroprotective signal, but sample sizes are small and independent Western replication remains limited.

Reports generally describe the compound as well tolerated, with local nasal irritation the complaint that recurs most often in intranasal solution studies. Because much of the published work involves small samples and short observation windows, the tolerability picture is incomplete rather than reassuring. No compound with a limited trial record should be described as free of adverse effects.

No. Semax has never been approved by the FDA as a drug product, and no large randomised controlled trial has been accepted by a regulator outside Russia, where it holds registered medicine status. In the United States it is legally supplied only as a research chemical for laboratory use, not for human or veterinary consumption.

Research-grade peptides are sold to researchers, laboratories and institutions for in vitro and documented research applications, not to consumers for personal use. Legitimate suppliers label material research-use-only, provide batch-specific certificates of analysis, and never supply dosing or administration guidance. Purchasers are responsible for compliance with their own institutional and jurisdictional rules.

Pricing varies widely by quantity, format, purity grade and whether the material is the unmodified sequence or a terminally modified analog. Liquid spray solutions and amidated variants typically price differently from lyophilised powder. The more useful comparison is not price per vial but price per milligram of net peptide content, which the certificate of analysis states.

Both are short synthetic peptides developed within the same Russian research programme and both are studied predominantly in intranasal solution form, but they descend from different parent molecules. Semax derives from the ACTH(4-10) fragment and is studied mainly in neuroprotection and cognition models, while Selank derives from the immunomodulatory peptide tuftsin and appears more often in anxiety-related research.

N-acetyl semax amidate is a terminally modified version of the sequence, acetylated at the N-terminus and amidated at the C-terminus. The literature associates those modifications with greater resistance to enzymatic cleavage than the unmodified peptide. It is a chemically distinct compound requiring its own documentation, not an interchangeable substitute in an existing protocol.

Reconstituted peptide solution is held at 2 to 8 degrees Celsius, protected from light, and used within a short window rather than stored long term. Repeated freeze-thaw cycling causes aggregation and loss of net peptide content that no visual check will detect. Lyophilised powder, by contrast, remains stable far longer at minus 20 degrees Celsius when kept dry.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA